Healthcare & Life Sciences: Drug Pricing Digest - June 2022 #2

Latham & Watkins LLP
Contact

Drug Pricing Initiatives: Congress and stakeholders continue to discuss drug pricing reform measures, including those that were originally part of H.R. 5376 (the Build Back Better Act, or BBBA).

In a related development, the Federal Trade Commission (FTC) announced that it will “launch an inquiry into the prescription drug middleman industry, requiring the six largest pharmacy benefit managers [(PBMs)] to provide information and records regarding their business practices.” The FTC will “scrutinize the impact of vertically integrated [PBMs] on the access and affordability of prescription drugs.”

Please see full publication below for more information.

LOADING PDF: If there are any problems, click here to download the file.

DISCLAIMER: Because of the generality of this update, the information provided herein may not be applicable in all situations and should not be acted upon without specific legal advice based on particular situations. Attorney Advertising.

© Latham & Watkins LLP

Written by:

Latham & Watkins LLP
Contact
more
less

PUBLISH YOUR CONTENT ON JD SUPRA NOW

  • Increased visibility
  • Actionable analytics
  • Ongoing guidance

Latham & Watkins LLP on:

Reporters on Deadline

"My best business intelligence, in one easy email…"

Your first step to building a free, personalized, morning email brief covering pertinent authors and topics on JD Supra:
*By using the service, you signify your acceptance of JD Supra's Privacy Policy.
Custom Email Digest
- hide
- hide